| Developers: | Variation Biotechnologies |
| Date of the premiere of the system: | August 2022 |
| Branches: | Pharmaceuticals, Medicine, Healthcare |
2022: Announcement of the first vaccine to prevent hepatitis B
In mid-August 2022, the first vaccine for the prevention of hepatitis B was registered in Russia. We are talking about the drug Sai-Bi-Vac, the distributor of which in the Russian Federation is Pharmsintez (its main shareholder is Rusnano).
 | Sai-Bi-Vak is the only vaccine registered in the Russian Federation for the prevention of hepatitis B, which ensures the formation of more powerful antiviral immunity, the press service of Rusnano reports. |  |
According to the general director of Pharmsintez Efim Prilezhaev, the studies conducted proved that the Sai-Bi-Vaka vaccine halves the likelihood of acute and chronic hepatitis V. He also noted that the drug provides longer protection, in particular, after vaccination "Sai-Bi-Vakoma," the study participants had 5.5 times more protective antibodies than vaccinated with another drug.
The vaccine was developed by the American Variation Biotechnologies, also known as VBI Vaccines. As noted by Corresponding Member of the Russian Academy of Sciences, Head of the Laboratory of Viral Hepatitis of the Research Institute of Vaccines and Serums named after I.I. Mechnikov Mikhail Mikhailov, the safety and effectiveness of the drug is established during the vaccination of more than 500,000 newborn children and adults. Vaccine proteins (Pre-S1 and Pre-S2) play an important role in increasing antibody concentration by stimulating a cellular or humoral immune response, thus providing increased vaccine efficacy in hepatitis B infection risk groups.
| | The advantage of Sai-bi-vak is that it guarantees protection in the emergency prevention of hepatitis B to doctors and, first of all, patients on hemodialysis, as well as residents of regions susceptible to natural disasters when there is a threat of mass infection, - said the head of the Department of Infectious Diseases of Adults and Epidemiology of St. Petersburg State Pediatric Medical University, MD, Professor Elena Esaulenko. | |
According to preliminary estimates, the need of the Russian pharmaceutical market for a new vaccine may amount to more than 300 thousand doses per year.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |